Dr. Tsao is currently the Chairman and CEO of PlexBio Co., Ltd. Dr. Tsao founded PlexBio in 2010.

Prior to his position as Chairman and CEO of PlexBio, Dr. Tsao was the founder and President of Zymed Laboratories, Genemed Synthesis Inc., and Genemed Biotechnologies, Inc. Zymed Laboratories, founded in 1980, provided antibody-based immune chemicals for cancer research and cancer diagnostic applications. The company was acquired by Invitrogen in 2005. Genemed Synthesis Inc., founded in 1995, provided custom DNA and Peptides synthesis services before being acquired by Genomic Resources Inc. in 2007. Genemed Biotechnologies, Inc., founded in 1987 specialized in contract manufacturing and contract R&D for molecular diagnostic and clinical pathology reagents before, and was acquired by Sakura Finetek USA, Inc. in 2015.

During the late 1980s and early 1990s, Dr. Tsao was a visiting professor at the Chinese Academy of Preventative Medicine in Beijing, an adjunct professor at Chang Gung Medical College in Taiwan, and a visiting scientist at Veterans General Hospital in Taiwan.

Dr. Tsao holds a doctorate in Biochemistry from Colorado State University and a B.S. in Agricultural Chemistry from National Chung-Hsing University, Taiwan. He has authored more than thirty scientific articles and three patents, and has been honored with the American Heart Association Post-Doctorate Fellowship. He has served in College of Natural Sciences External Advisory Committee of Colorado State University, and is currently the director of the Monte Jade Science and Technology Association.

Dr. Lee co-founded the company in May 2009 as Chairman of the Board. Dr. Lee is a general partner and co-founder of AmKey Ventures, LLC, a venture management company specializing in investments in the biotech and pharmaceutical fields. Dr. Lee is a co-founder of Pharmout Labs, Pharmdel Inc., and BioKey Inc.

Dr. Lee has extensive experience in the pharmaceutical industry. He worked at Syntex for 13 years, as well as early stage biomedical companies Sonus and Shaman Pharmaceuticals for 7 years. Dr. Lee is an internationally known pioneer in the field of steroid hormones research. Dr. Lee has in-depth experience in analytical methods development and validation for New Drug Applications as well as various applications to the Food & Drug Administration.

Dr. Lee earned his Ph.D. in Chemistry from the State University of New York at Buffalo and his B.S. in Biochemistry from National Taiwan University.

Dr. Lee co-founded the company in May 2009 as a Board Member, President, and Chief Executive Officer. Prior to joining PharmTak, Inc., he was Chief Technical Officer and General Manager, Drug Products for Waterstone Pharmaceuticals, Inc. Dr. Lee was Vice President of Manufacturing at Replidyne, Inc. in Louisville, Colorado. During his stay in Replidyne, he was in charge of developing a topical product for an MRSA antibacterial, tablet and powder formulations of a new class antibiotic and a colonic delivery formulation for a new antibiotic.

Dr. Lee was Vice President, Development at Cellegy Pharmaceuticals in South San Francisco, California. Dr. Lee joined Cellegy in 1998 and built the Development Group to develop topical, transdermal, and skincare products. He was responsible for developing Nitroglycerin Ointment and Testosterone Transdermal Gel products during his stay in Cellegy, and both products were successfully marketed in 26 European and Asian countries. After the successful acquisition of Vaxis Therapeutics by Cellegy, Dr. Lee assumed the responsibility of overseeing the CMC of a developmental vaginal gel product for HIV prevention.

Prior to Cellegy, Dr. Lee worked as Director of Pharmaceutical Development at Cytel, Inc.; Division Director of Formulation Development at Oread Laboratories; and Director of Formulation Development at Syntex Research/Roche Global Development. Besides the Department Director position at Syntex/Roche, Dr. Lee also served as CMC Leader for five years for all Animal Health projects and one Human project. Dr. Lee’s effort at Syntex/Roche resulted in five FDA approved NDA/NADA. Dr. Lee is an author or co-author for a book chapter, 14 research papers or monographs, and 9 issued patents.

Dr. Lee received his M.S. and Ph.D. in Pharmaceutical Chemistry from the University of Kansas, Lawrence, Kansas.